Although Lincoln Park Capital would not dare investing millions of dollars on long shot companies, we know they have smart people with an army of researchers and analysts that will find ways to exploit the LPC deal with Elite to make money. A quick Web search for LPC deals reveals other similar deals, more or less, with other companies having financing issues such as Elite in which financing dollars were exchange for common stocks. LPC like all institutional investors is no stranger to investing stocks for the long-term and short-term. They are basically "rinsing-and-repeating" the same formula that they've use countless of times to skim off profits from the spread between the bid and ask prices. A more thorough investigation will show that companies involved in deals with LPC had shown a noticeable decline in the PPS. Elite has stated in recent SEC Prospectus filings, that it has no knowledge if LPC will hold shares for the short-term or long-term. Just to give LPC the benefit of the doubt, imo, they may be holding a set amount for the long-term. Let me emphasize that this in no way, severly hurts Elite in the long-run; although, the PPS dilution is being felt in the short-run. Elite is able to secure the financing for the purposes of continuing with its research and development and to start clinical trials. In the meantime, the entry PPS for Elite is indeed attractive for both new and current investors. Cheers!
Market Data 
Markets 
AI
